|
1 |
Blinded, multicenter evaluation of drug-induced changes in contractility using human-induced pluripotent stem cell-derived cardiomyocytes
|
Toxicological Sciences |
|
|
2 |
Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell–derived Cardiomyocytes: fit for purpose or forever elusive?
|
Annual review of pharmacology and toxicology |
|
|
3 |
CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
|
European Heart Journal |
|
|
4 |
Cellular cardiomyoplasty for myocardial infarction: a 2014 evidence based update
|
Acta Medica Indonesiana |
|
